Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT ID: NCT07266493

Last Updated: 2025-12-05

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-01
• Study Completion Date: 2026-12-01

Brief Summary

This single center, prospective, single arm clinical study aims to evaluate the clinical efficacy and safety of Envafolimab combined with albumin bound paclitaxel and carboplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma.

Conditions

Esophageal Squamous Cell Carcinoma; Neoadjuvant Therapy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental: Envafolimab+Chemotherapy Group（EC Group）

Envafolimab: 150mg, subcutaneous injection, administered on days 1, 8, and 15, treated for 3 weeks, followed by a 1-week rest period; Albumin bound paclitaxel: administered on days 1, 8, and 15, 100 mg/m2, IV , treated for 3 weeks, followed by a 1-week rest period; Carboplatin: administered on days 1, AUC 5, treated for 3 weeks, followed by a 1-week rest period. All patients will receive treatment with Envafolimab combined with albumin bound paclitaxel and carboplatin for three weeks, followed by one week of rest and a 28 day treatment cycle, for a total of two cycles. Then, the tumor condition of the patients will be evaluated to determine whether surgical treatment is feasible.

Group Type: EXPERIMENTAL

Chemotherapy （Albumin bound paclitaxel and Carboplatin）

Intervention Type: DRUG

Albumin bound paclitaxel: administered on days 1, 8, and 15, 100 mg/m2, IV , treated for 3 weeks, followed by a 1-week rest period; Carboplatin: administered on days 1, AUC 5, treated for 3 weeks, followed by a 1-week rest period.

Interventions

Chemotherapy （Albumin bound paclitaxel and Carboplatin）

Albumin bound paclitaxel: administered on days 1, 8, and 15, 100 mg/m2, IV , treated for 3 weeks, followed by a 1-week rest period; Carboplatin: administered on days 1, AUC 5, treated for 3 weeks, followed by a 1-week rest period.

Intervention Type: DRUG

Other Intervention Names

Albumin bound paclitaxel and Carboplatin

Eligibility Criteria

Inclusion Criteria

• The subjects voluntarily joined this study, were able to sign the informed consent form, and had good compliance;
• Age ≥ 18 years old (when signing the informed consent form);
• ECOG score 0-1 points;
• Diagnosed with operable esophageal squamous cell carcinoma through pathological diagnosis (pathological tissue/cytology) and imaging;
• The clinical TNM staging is T2-4aNxM0
• Patients assessed to require routine neoadjuvant therapy;
• Have not received immunotherapy, chemotherapy, targeted therapy, or radiotherapy in the past;
• Expected survival ≥ 12 weeks

Exclusion Criteria

• The subjects have any active autoimmune diseases or a history of autoimmune diseases (such as but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, pituitary inflammation, vasculitis, nephritis, thyroid dysfunction (hyperthyroidism/hypothyroidism), and the use of drugs cannot maintain thyroid function within the normal range, or patients who have undergone thyroid surgery and require long-term replacement therapy with thyroid hormone and other drugs after surgery); Subjects with vitiligo or complete remission of childhood asthma who do not require any intervention in adulthood may be included; Asthma in which subjects require bronchodilators for medical intervention cannot be included
• The subject has previous or concurrent malignant tumors;
• Patients who have received systemic anti-tumor therapy in the past;
• Individuals who have undergone significant surgical treatment, open biopsy, or significant traumatic injury within 28 days prior to the start of treatment; Or there may be wounds or fractures that have not been cured for a long time;
• There is a risk of bleeding, coagulation dysfunction, or currently undergoing thrombolytic therapy; Or have experienced esophageal or gastric variceal rupture bleeding in the past 6 months;
• It is known that the subject has a history of allergies to large molecule protein preparations or drug ingredients used;
• Subjects with any severe and/or uncontrolled illnesses
• Ascites or pleural effusion with clinical symptoms cannot be controlled with medication and require therapeutic puncture or drainage;
• The subject is known to have a history of substance abuse, alcoholism, or drug use;
• The researchers believe that participants should be excluded from this study, for example, if the researchers determine that there are other factors that may cause the study to be terminated midway

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Zhongshan Hospital

OTHER

Sponsor Role: lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Responsible Party

Ge Di

Ge Di., MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Shanghai Zhongshan Hospital

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Di Ge, MD

Role: CONTACT

gedi@zs-hospital.sh.cn

86-18202188606

Facility Contacts

Di Ge, MD

Role: primary

gedi@zs-hospital.sh.cn

86-18202188606

Other Identifiers

B2023-222R

Identifier Type: -

Identifier Source: org_study_id